-
Publication Venue For
-
Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.
2022
-
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD..
76:1030-1041.
2022
-
Value of liver biopsy in the diagnosis of drug-induced liver injury..
76:1070-1078.
2022
-
Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study..
76:832-840.
2022
-
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B..
76:311-318.
2022
-
Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease..
75:623-633.
2021
-
Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI..
75:333-341.
2021
-
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis..
75:25-33.
2021
-
Changes in frailty are associated with waitlist mortality in patients with cirrhosis..
73:575-581.
2020
-
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum..
73:680-693.
2020
-
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)"..
72:592-593.
2020
-
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial..
72:431-440.
2020
-
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis..
72:25-33.
2020
-
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study..
71:486-497.
2019
-
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial..
70:684-691.
2019
-
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial..
70:483-493.
2019
-
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices..
70:412-422.
2019
-
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options..
69:1365-1370.
2018
-
The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine..
69:1317-1325.
2018
-
Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes..
69:359-367.
2018
-
Towards a definite mouse model of NAFLD..
69:272-274.
2018
-
Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma..
68:1144-1152.
2018
-
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease..
68:1063-1075.
2018
-
Hedgehog signalling in liver pathophysiology..
68:550-562.
2018
-
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis..
67:263-271.
2017
-
Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice..
65:354-362.
2016
-
Iron overload in hereditary tyrosinemia type 1 induces liver injury through the Sp1/Tfr2/hepcidin axis..
65:137-145.
2016
-
Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency..
64:370-379.
2016
-
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin..
64:29-36.
2016
-
Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease..
63:962-970.
2015
-
Drug-induced liver injury: Interactions between drug properties and host factors..
63:503-514.
2015
-
Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL)..
62:346-353.
2015
-
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET..
62:286-293.
2015
-
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection..
61:1238-1246.
2014
-
Reply to: "depletion of hepatic stellate cells: have Kupffer cells lost their bad neighbor?"..
61:715-716.
2014
-
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response..
60:748-756.
2014
-
A novel mouse model of depletion of stellate cells clarifies their role in ischemia/reperfusion- and endotoxin-induced acute liver injury..
60:298-305.
2014
-
Towards a better characterization of cirrhosis-associated cardiomyopathy?.
59:192-193.
2013
-
Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis..
58:778-784.
2013
-
IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients..
58:402-403.
2013
-
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients..
56:313-319.
2012
-
Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo..
55:1272-1280.
2011
-
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C..
55:1195-1200.
2011
-
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease..
55:666-672.
2011
-
Hedgehog signaling in the liver..
54:366-373.
2011
-
Microarchitecture of the liver: a jigsaw puzzle..
54:187-188.
2011
-
Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3..
53:57-66.
2010
-
Liver transplantation for glycogen storage disease type Ia..
51:483-490.
2009
-
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
2017